Iopanoic acid

Iopanoic acid

Systematic (IUPAC) name
(RS)-2-[(3-Amino-2,4,6-triiodophenyl)methyl]butanoic acid
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Identifiers
CAS Registry Number	96-83-3
ATC code	V08AC06
PubChem	CID 3735
DrugBank	DB08946 N
ChemSpider	3604
UNII	FE9794P71J Y
KEGG	D01014
ChEMBL	CHEMBL867 Y
Chemical data
Formula	C11H12I3NO2
Molecular mass	570.93 g/mol
SMILES CCC(CC1=C(C(=C(C=C1I)I)N)I)C(=O)O
InChI InChI=1S/C11H12I3NO2/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5H,2-3,15H2,1H3,(H,16,17) Key:OIRFJRBSRORBCM-UHFFFAOYSA-N

Iopanoic acid is an iodine-containing radiocontrast medium used in cholecystography. Both iopanoic acid and ipodate sodium are potent inhibitors of thyroid hormone release from thyroid gland, as well as of peripheral conversion of thyroxine (T₄) to triiodothyronine (T₃). These compounds inhibit 5'deiodinase (5'DID-1 and 5'DID-2) enzymes, which catalyse T₄-T₃ conversion in the thyroid cell, liver, kidney, skeletal muscle, heart, brain, pituitary. This accounts for the dramatic improvement in both subjective and objective symptoms of hyperthyroidism, particularly when they are used as an adjunctive therapy with thioamides (propylthiouracil, carbimazole). These are less toxic, as iodine is covalently bound in these compounds. They can be used in the treatment of patients with severe thyrotoxicosis (thyroid storm) and significant morbidity (e.g., myocardial infarction, or stroke) for rapid control of elevated plasma triiodothyronine concentrations. The use of iopanoic acid for treatment of thyrotoxicosis has been discontinued in the United States.

In addition to inhibiting deiodinase enzymes, iopanoic acid is also a substrate of type 1 deiodinase. Iopanoic acid underwent monodeiodination in the presence of type 1 deiodinase in a microsomal mouse liver preparation.^[1]

References